Dipexium Pharmaceuticals Announces Participation in September Investor Conferences

NEW YORK, Aug. 24, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced plans to participate in two September investor conferences:

• Friday, September 9, 2016 at the NewsMakers in the Biotechnology Industry Conference in New York City. David P. Luci, President & Chief Executive Officer, will present a corporate overview at 2:00 p.m. ET.
  
  
• Monday, September 12, 2016 at the Rodman & Renshaw 18^th Annual Global Investment Conference in New York City. David P. Luci, President & Chief Executive Officer, will present a corporate overview at 12:05 p.m. ET.

To access the live audio webcasts of these presentations, please log on through a link in the Investor Relations section of Dipexium's website at www.dipexiumpharmaceuticals.com, under the IR Calendar tab. A replay of the webcasts will be available for 30 days after the live events.

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). For more information, visit www.dipexiumpharmaceuticals.com.

Company Contacts:

David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
212-269-2834
[email protected]

David Garrett
Vice President, Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.
212-269-2834
[email protected]

© 2016 Dipexium Pharmaceuticals, Inc.  All rights reserved.

SOURCE Dipexium Pharmaceuticals, Inc.

Related Links

http://www.dipexiumpharmaceuticals.com